NDATOPICALLOTION
Approved
Aug 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BETATREX (betamethasone valerate) by Merck & Co. is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. Approved for psoriasis, atopic eczema, hand eczema. First approved in 1983.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETATREX is a topical corticosteroid lotion containing betamethasone valerate that treats inflammatory skin conditions including psoriasis, atopic eczema, and hand eczema. It works through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms that reduce skin inflammation and itching. The drug is absorbed through intact skin and metabolized hepatically with renal excretion.
LOE Approaching
As a 40+ year-old product approaching loss of exclusivity, BETATREX brand teams are transitioning to defensive strategies and niche positioning rather than growth investments.
Mechanism of Action
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indications (3)
Worked on BETATREX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.